If You Invested in NYXOAH S A (NYXH)

Nyxoah SA (NASDAQ/Euronext: NYXH) is a medical technology company focused on the development and commercialization of solutions to treat obstructive sleep apnea (OSA), a sleep-disordered breathing condition associated with increased mortality risk and cardiovascular comorbidities. According to company disclosures, Nyxoah concentrates on neuromodulation-based therapies and has built its platform around the Genio system, a hypoglossal neurostimulation therapy designed for patients with moderate to severe OSA.

Core business and Genio system

Nyxoah describes its lead solution, the Genio system, as a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA. The therapy is intended for adult patients with an Apnea-Hypopnea Index (AHI) greater than or equal to 15 and less than or equal to 65, as reflected in company announcements about regulatory approvals. The system is positioned as an alternative for OSA patients, including those who do not tolerate continuous positive airway pressure (CPAP), by stimulating the hypoglossal nerve to help maintain airway patency during sleep.

Company communications emphasize that Genio is externally powered and does not rely on an implanted battery. Nyxoah highlights bilateral stimulation of the hypoglossal nerve and a user-centered design, with an external activation chip that can be upgraded over time. The company also notes compatibility of the system with full-body 1.5 and 3T MRI, based on statements from clinicians involved in early commercial use.

Regulatory milestones and clinical foundations

Nyxoah reports that the Genio system received its European CE Mark in 2019 following the successful completion of the BLAST OSA study. The company further states that, after positive outcomes from the BETTER SLEEP study, it obtained CE mark approval to expand therapeutic indications to patients with Complete Concentric Collapse (CCC), a group it notes as being contraindicated in competitors’ therapy.

In the United States, Nyxoah has disclosed that the U.S. Food and Drug Administration (FDA) approved the Genio system in August 2025 as a prescription-only device for a subset of adult patients with moderate to severe OSA within the specified AHI range. The company links this approval to positive outcomes from the DREAM IDE pivotal study. These regulatory milestones form the backbone of Nyxoah’s commercialization strategy in both European markets and the U.S.

Commercialization and market focus

Nyxoah describes itself as focused on the development and commercialization of its OSA therapy platform. Company updates indicate an emphasis on U.S. commercialization following FDA approval and on advancing commercial rollout in initial target markets outside the United States. The company reports training surgeons on the Genio system, activating accounts in the U.S., and performing commercial implants in both the U.S. and European countries such as the Netherlands.

In its own statements, Nyxoah links revenue growth to the early stages of U.S. commercialization and to broader international expansion. It also notes that proceeds from equity offerings and convertible bond financings are intended to support commercialization activities, gather additional clinical data, fund research and development related to Genio system upgrades and manufacturability, and explore potential collaboration opportunities in monitoring and diagnostics for OSA.

Capital markets presence

Nyxoah has disclosed that it completed two initial public offerings: one on Euronext Brussels in September 2020 and another on NASDAQ in July 2021. The company continues to access capital markets through private placements, registered direct offerings, underwritten public offerings and convertible bond financings, as detailed in its press releases and Form 6-K filings. These financings are described as supporting U.S. commercialization of Genio, expansion in selected international markets, and ongoing clinical and development activities.

Research, development and clinical strategy

Company reports indicate that Nyxoah continues to invest in research and development related to the Genio system, including upgrades, redesign for manufacturability and cost reduction initiatives. Nyxoah also mentions support for physician-initiated clinical research projects related to OSA patient treatments and the maintenance of a pipeline of new technologies, particularly in monitoring and diagnostics for OSA. In regulatory filings, the company discusses clinical studies such as BLAST OSA, BETTER SLEEP, DREAM IDE and ACCCESS, positioning these as central to its evidence base and regulatory strategy.

Nyxoah also notes that it has reorganized its global R&D function and expects to transition ongoing R&D activities to the United States and Belgium, according to its SEC filings. The company’s risk factor disclosures further highlight the importance of intellectual property protection and ongoing litigation in the medical device industry, including patent disputes related to hypoglossal nerve stimulation technologies.

Corporate profile and sector classification

Nyxoah SA is categorized in the surgical and medical instrument manufacturing industry within the broader manufacturing sector. The company identifies itself as a health-technology and medical technology business, with operations centered on a single primary commercial product platform, the Genio system, for the treatment of obstructive sleep apnea.

Through its disclosures, Nyxoah articulates a vision that OSA patients should enjoy restful nights and feel enabled to live their lives to the fullest. Its business model, as described in company communications, is built around bringing a neuromodulation-based OSA therapy from clinical development through regulatory approval to commercial adoption in targeted markets, supported by capital markets financing and ongoing clinical and R&D investment.

Key historical milestones

• European CE Mark for the Genio system in 2019 following the BLAST OSA study.
• CE mark expansion to include Complete Concentric Collapse (CCC) patients after BETTER SLEEP study outcomes.
• Initial public offering on Euronext Brussels in September 2020.
• Initial public offering on NASDAQ in July 2021.
• Positive DREAM IDE pivotal study outcomes and FDA approval of Genio for a defined subset of adult OSA patients in August 2025 as a prescription-only device.